feed,title,long_url,short_url
Benzinga,UCB's Bispecific Marks Phase 3 Win For Second Psoriatic Arthritis Study,https://benzinga.com/general/biotech/22/01/25160784/ucbs-bispecific-marks-phase-3-win-for-second-psoriatic-arthritis-study,https://bit.ly/3rH0JZK
Benzinga,Here's Why Northland Sees Huge Upside In Luminar Tech,https://benzinga.com/analyst-ratings/analyst-color/22/01/25161558/heres-why-northland-sees-huge-upside-in-luminar-tech,https://bit.ly/35dEvHp
